This is a routine proxy filing with no financial data or operational catalysts. Monitor the shareholder vote on Proposal 4 (Arkin's CEO appointment) and Proposal 6 (capital increase) for governance signals, but no near-term price catalyst is present.
Price Chart
Executive Summary
Sol-Gel Technologies filed its proxy statement for the Annual Meeting of Shareholders scheduled for November 17, 2026. The agenda includes routine items: re-appointment of auditors, re-election of directors and external directors, approval of controlling shareholder Moshe Arkin as CEO for a three-year term (effective January 1, 2027), a proposed name change to 'Sol-Gel Therapeutics Ltd.' or 'Sol-Gel Dermatology Ltd.', and an increase in registered share capital from 5,000,000 to 8,000,000 ordinary shares. The filing is administrative and contains no material financial data or operational updates.
Key Facts
- Annual Meeting scheduled for November 17, 2026; record date October 7, 2026.
- Proposal to appoint Moshe Arkin (controlling shareholder, ~56% ownership) as CEO for a three-year term starting January 1, 2027, replacing his interim role.
- Proposal to increase registered share capital from 5,000,000 to 8,000,000 ordinary shares (authorized, not issued).
- Proposal to change company name to 'Sol-Gel Therapeutics Ltd.' or 'Sol-Gel Dermatology Ltd.' within 12 months.
- Re-election of four directors and two external directors (Ran Gottfried, 82, and Yuval Yanai, 74) proposed.
- As of October 6, 2026, the company had 3,273,999 ordinary shares issued and outstanding.
- Moshe Arkin receives no compensation for his roles as Executive Chairman and CEO, only reimbursement for out-of-pocket expenses.
Financial Impact
No financial figures reported. The authorized share capital increase from 5M to 8M shares does not itself issue shares or raise capital.
Risk Factors
- Controlling shareholder Moshe Arkin (56% ownership) serving as both Executive Chairman and CEO concentrates governance power, though he receives no compensation.
- Authorized share capital increase (5M to 8M shares) creates potential future dilution, though no issuance is authorized by this proposal alone.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-004718 |
| Exhibit: exhibit_99-2.htm | 0001178913-26-004718 |
| Document: zk2636198.htm | 0001178913-26-004718 |
| Document: 0001178913-26-004718-index-headers.html | 0001178913-26-004718 |
| Document: 0001178913-26-004718-index.html | 0001178913-26-004718 |
| Document: 0001178913-26-004718.txt | 0001178913-26-004718 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 6-K | $75.64 | awaiting T+20 | — | $68.61 (−9.29%) |
Sep 30, 2026 27d ago | 6-K | $74.28 | awaiting T+20 | — | $68.61 (−7.63%) |
Sep 17, 2026 5w ago | 6-K | $64.54 $68.70 | ▲ +6.45% | ▲ +4.99% | $68.61 (+6.31%) |
Sep 14, 2026 6w ago | Insider Buy | $64.40 $68.30 | ▲ +6.06% | ▲ +3.08% | $68.61 (+6.55%) |
Sep 9, 2026 6w ago | Insider Buy | $66.79 $70.34 | ▲ +5.32% | ▲ +2.94% | $68.61 (+2.73%) |
Sep 3, 2026 7w ago | Insider Buy | $69.52 $78.95 | ▲ +13.56% | ▲ +12.96% | $68.61 (−1.30%) |
Aug 31, 2026 8w ago | Insider Buy | $69.52 $74.28 | ▲ +6.85% | ▲ +6.53% | $68.61 (−1.30%) |
Aug 20, 2026 9w ago | 6-K | $78.50 $64.54 | ▼ −17.78% | ▼ −17.78% | $68.61 (−12.59%) |
Aug 20, 2026 9w ago | Press Release | $78.50 $64.54 | ▼ −17.78% | ▼ −17.78% | $68.61 (−12.59%) |
Aug 14, 2026 10w ago | Insider Buy | $83.01 $64.40 | ▼ −22.42% | ▼ −20.44% | $68.61 (−17.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers